Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03860246 · ClinicalTrials.gov registry record

Atrial Fibrillation Screening in Nursing Homes

A clinical trial of Atrial Fibrillation, sponsored by State University of New York at Buffalo.

Completed
Registry status
245
Enrollment target
1
Study location

NCT03860246: Completed study of Atrial Fibrillation, sponsored by State University of New York at Buffalo.

NCT03860246 is a study of Atrial Fibrillation that has completed, run by State University of New York at Buffalo. The registered enrollment target is 245 participants, below the 2,996-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03860246, a study of Atrial Fibrillation, has completed, sponsored by State University of New York at Buffalo.

COMPLETED
Registry status
245 participants
Enrollment target
1
Study location

Study Summary

This study was designed to screen high risk patients in nursing homes for atrial fibrillation with intermittent electrocardiogram (ECG) recordings using a portable, smartphone-based, mobile ECG recording device (Kardia Mobile, AliveCor, Inc.). The investigators hypothesized that screening patients with 2 or more risk factors for atrial fibrillation would yield a higher incidence of atrial fibrillation compared to prior studies.

Primary Outcome

number of participants with atrial fibrillation on any of four rhythm recordings

Conditions Studied

Atrial Fibrillation

Interventions

  • DIAGNOSTIC_TEST Portable ECG monitor

Study Locations (1)

New York

  • CTRC - Buffalo

Trial Details

FieldValue
Enrollment Target 245 participants
Start Date 2018-02-01
Est. Completion 2018-11-01
State University of New York at Buffalo

243 total trials

What the finished NCT03860246 record still lists

NCT03860246 is an observational study that tracks outcomes without assigning an intervention. The registered 245 participants enrollment target is mid-sized for trials with a published cap, below the 2,996-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (92% lower).

The record links to 1 condition, with Atrial Fibrillation appearing as the primary indexed condition, and to 1 intervention - of which Portable ECG monitor is the first listed.

NCT03860246 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT03860246 about?

NCT03860246 is a clinical study titled "Atrial Fibrillation Screening in Nursing Homes". This study was designed to screen high risk patients in nursing homes for atrial fibrillation with intermittent electrocardiogram (ECG) recordings using a portable, smartphone-based, mobile ECG recording device (Kardia Mobile, AliveCor, Inc.). The investigators hypothesized that screening patients w...

What is the current status of trial NCT03860246?

This trial is currently completed. The enrollment target is 245 participants. The study started on 2018-02-01. Estimated completion is 2018-11-01.

What conditions does trial NCT03860246 study?

This clinical trial studies the following conditions: Atrial Fibrillation.

What interventions are being tested in trial NCT03860246?

The interventions under investigation include: Portable ECG monitor (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT03860246?

This trial is sponsored by State University of New York at Buffalo, which has 243 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03860246 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Atrial Fibrillation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03860246's enrollment target sits among peer trials

245 94th of 202 higher than 109 of 202 other Atrial Fibrillation trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Atrial Fibrillation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03645928 · 245 participants · Phase 2

    Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

  • NCT04718168 · 245 participants · NA

    GORE® ENFORM Biomaterial Product Study

  • NCT05145127 · 245 participants · Phase 3

    Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors

  • NCT05446259 · 245 participants

    Degenerative Cervical Myelopathy Repository

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT03860246, the US trial registry maintained by the National Library of Medicine. NCT03860246 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.